Modern classification of breast cancer: Should we stick with morphology or convert to molecular profile characteristics

Advances in Anatomic Pathology

Volumn 18, Issue 4, 2011, Pages 255-267

  Rakha, Emad A ^a,b   Ellis, Ian O ^a,b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

breast cancer; classification; molecular profile; morphology; routine practice

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MESSENGER RNA; P CADHERIN; PROTEIN P53; RNA; TAMOXIFEN;

BREAST CANCER; CANCER MORPHOLOGY; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER STAGING; GENE EXPRESSION PROFILING; GENETIC PROCEDURES; LYMPH NODE; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TAXONOMY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 79959254818     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318220f5d1     Document Type: Review

References (186)

1. Williams C, Brunskill S, Altman D, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess. 2006;34:1-204.
2. Hind D, Ward S, De Nigris E, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;26:1-134.
3. Polychemotherapy for early breast cancer: an overview of the randomised trials: early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;9132:930-942.
4. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
5. Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009;11:1070-1076.
6. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;8:1319-1329.
7. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;3:207-219.
8. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;20:1456-1466. (Pubitemid 26340047)
9. Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;1:73-83. (Pubitemid 350256943)
10. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;7:2302-2310.
11. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;19:3153-3158.
12. Westenend PJ, Meurs CJ, Damhuis RA, Tumour size and vascular invasion predict distant metastasis in stage I breast cancer: grade distinguishes early and late metastasis. J Clin Pathol. 2005;2:196-201. (Pubitemid 40193807)
13. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type: relationship with survival in a large study with long-term follow-up. Histopathology. 1992;6:479-489.
14. Fisher ER, Redmond C, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP): prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer. 1990;9(suppl):2121-2128. (Pubitemid 20140911)
15. Hanrahan EO, Valero V, Gonzalez-Angulo AM, et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol. 2006;13:2113-2122. (Pubitemid 46628472)
16. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846-3852. (Pubitemid 47477259)
17. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCO POOL-A European database for 16,944 cases of breast cancer. Eur J Cancer. 2009;1:56-71.
18. Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, et al. Disease-Disfree survival and prognostic significance of metastatic lymph node ratio in T1-T2 N positive breast cancer patients: a population registry-based study in a European country. World J Surg. 2009;8:1659-1664.
19. Ichikura T, Tomimatsu S, Okusa Y, et al. Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer. J Clin Oncol. 1993;10:1894-1900. (Pubitemid 23304613)
20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;1:118-145. (Pubitemid 350003059)
21. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009:S1-S21; quiz S22-S23.
22. Carlson RW, Goldstein LJ, Gradishar WJ, et al. NCCN Breast Cancer Practice Guidelines: the National Comprehensive Cancer Network. Oncology (Williston Park). 1996;11(suppl):47-75.
23. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;7: 966-978.
24. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol. 2009;27:Abstract 543.
25. Pathology reporting of breast disease. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. January 2005. NHSBSP Pub. No 58.
26. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;33:5287-5312.
27. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;16:2784-2795.
28. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988;26:1681-1692.
29. Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998;5366:1077-1082. (Pubitemid 28234949)
30. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;2:207-211. (Pubitemid 28455458)
31. Schweiger MR, Kerick M, Timmermann B, et al. Genome-wide massively parallel sequencing of formaldehyde fixedparaffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One. 2009;5:e5548.
32. Liang P, Pardee AB, Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 1992;5072:967-971.
33. Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science. 1995;5235:484-487.
34. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;1(suppl):33-37. (Pubitemid 29031489)
35. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;6797:747-752.
36. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;19:10869-10874. (Pubitemid 32878711)
37. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;3:340-350. (Pubitemid 40993329)
38. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;11:1665-1671. (Pubitemid 46622137)
39. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;6871:530-536.
40. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;9460:671-679. (Pubitemid 40260888)
41. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;6:607-616. (Pubitemid 38748922)
42. Zhang Y, Sieuwerts AM, McGreevy M, et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. 2009;2:303-309.
43. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;4:732-740. (Pubitemid 46224172)
44. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;26:4236-4244. (Pubitemid 46630780)
45. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;11:1294-1300. (Pubitemid 44706932)
46. Naderi A, Teschendorff AE, Barbosa-Morais NL, et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007;10:1507-1516. (Pubitemid 46340809)
47. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006;10:5278-525286.
48. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;10:5974-5975979.
49. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;5:362-375. (Pubitemid 36437922)
50. Seth A, Kitching R, Landberg G, et al. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 2003;3A:2043-20451.
51. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;21:7167-7175. (Pubitemid 37413454)
52. Zhao H, Langerod A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;6:2523-2536. (Pubitemid 38691844)
53. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55.
54. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001;20:11462-11467. (Pubitemid 32928751)
55. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003;9369:1590-1596. (Pubitemid 36578995)
56. Warwick J, Tabar L, Vitak B, et al. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer. 2004;7:1331-1336. (Pubitemid 38366834)
57. Balslev I, Axelsson CK, Zedeler K, et al. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat. 1994;3:281-290. (Pubitemid 24351375)
58. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;10:2006-2014. (Pubitemid 40605106)
59. Crump M, Goss PE, Prince M, et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;1:66-69. (Pubitemid 26019998)
60. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;12:2917-2924. (Pubitemid 11191732)
61. Smith JA III, Gamez-Araujo JJ, Gallager HS, et al. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer. 1977;2:527-532. (Pubitemid 8063513)
62. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;1-3:227-237. (Pubitemid 29056098)
63. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;17:3628-3636. (Pubitemid 34983222)
64. Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;3:333-340.
65. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol. 1997;6:447-451. (Pubitemid 127725216)
66. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;1:181-187. (Pubitemid 19032001)
67. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993;11:2090-2100. (Pubitemid 23332244)
68. Seidman JD, Schnaper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer. 1995;1:65-71.
69. Kollias J, Elston CW, Ellis IO, et al. Early-onset breast cancer-histopathological and prognostic considerations. Br J Cancer. 1997;9:1318-1323. (Pubitemid 27179822)
70. Neville AM, Bettelheim R, Gelber RD, et al. Factors predicting treatment responsiveness and prognosis in nodenegative breast cancer. the International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;5:696-705.
71. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0): assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am. 1990;4:937-962. (Pubitemid 20223179)
72. Elston CW, Ellis IO. The Breast. In: Elston CW, Ellis IO, eds. Systemic Pathology. Vol 13. 3rd ed. Edinburgh: Churchill Livingstone; 1998:239-249.
73. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary nodepositive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol. 2000;10:2059-2069. (Pubitemid 30324359)
74. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;9:1914-1921. (Pubitemid 19267813)
75. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;4:207.
76. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;4:262-272. (Pubitemid 43264710)
77. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;21:10292-10301. (Pubitemid 44799747)
78. Thomas JS, Kerr GR, Jack WJ, et al. Histological grading of invasive breast carcinoma - a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology. 2009;6:724-731.
79. Page DL, Gray R, Allred DC, et al. Prediction of nodenegative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol. 2001;1:10-18. (Pubitemid 32178665)
80. Walker RA. Prognostic and Predictive Factors in Breast Cancer. 1st ed. New York: Informa Health Care; 2003:10-17.
81. Sundquist M, Thorstenson S, Brudin L, et al. Applying the nottingham prognostic index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat. 1999;1:1-8.
82. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;16:5158-5165.
83. Pinder SE, Murray S, Ellis IO, et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998;8:1529-1539. (Pubitemid 28465470)
84. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;1:10-26. (Pubitemid 34062395)
85. Rivadeneira DE, Simmons RM, Christos PJ, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;1:1-6; discussion 6-8.
86. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997;10:1918-1922. (Pubitemid 27200375)
87. Johnson HA, Bond VP. A method of labeling tissues with tritiated thymidine in vitro and its use in comparing rates of cell proliferation in duct epithelium, fibroadenoma, and carcinoma of human breast. Cancer. 1961;14:639-643.
88. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptornegative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;1:26-35. (Pubitemid 40128091)
89. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;6:560-569. (Pubitemid 44200649)
90. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2001;30:27-35.
91. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;4:R65.
92. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006;6:216.
93. van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;7:675-681. (Pubitemid 38901478)
94. Clayton F, Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas: mitotic count is the best single predictor. Cancer. 1991;6:1309-1317.
95. Medri L, Volpi A, Nanni O, et al. Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol. 11:1067-1075.
96. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. In: Deville P, Tavassoli F, eds. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC press; 2003:19-23.
97. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology. 1995;3:219-226.
98. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol. 1999;3:209-223. (Pubitemid 29424143)
99. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;1:99-104.
100. Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;5:1442-1448. (Pubitemid 29220850)
101. Dawson PJ, Ferguson DJ, Karrison T. The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 1982;10:2131-2138. (Pubitemid 13203620)
102. Schnitt SJ, Connolly JL, Harris JR, et al. Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer. 1984;5:1049-1057. (Pubitemid 14196481)
103. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994;1:41-47.
104. Clemente CG, Boracchi P, Andreola S, et al. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer. 1992;6:1396-1403.
105. Davis BW, Gelber R, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985;12:1212-1218. (Pubitemid 16170145)
106. Dawson PJ, Karrison T, Ferguson DJ, Histologic features associated with long-term survival in breast cancer. Hum Pathol. 1986;10:1015-1021. (Pubitemid 17180636)
107. Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011;3:358-365.
108. De Laurentiis M, Gallo S, Placido De, et al. A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer. 1996;10:1241-1247. (Pubitemid 26162340)
109. Ryden L, Jonsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005;2:256-264. (Pubitemid 40136540)
110. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;2:111-117. (Pubitemid 30185917)
111. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res. 2007;5:R65.
112. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;10:1569-1583.
113. Ogawa K, Toita T, Kakinohana Y, et al. Radiation therapy following mastectomy for axillary node-positive breast cancer: indication of chest wall irradiation. Oncol Rep. 2000;5:1107-1112.
114. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;9472:1687-1717.
115. Osborne CK, Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;3:227-238. (Pubitemid 29054556)
116. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987;8552:171-175.
117. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;9114:1451-1467.
118. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;22:3758-3767.
119. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;21:1529-1542. (Pubitemid 26374506)
120. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;10:1973-1979. (Pubitemid 46606386)
121. Ferno M, Stal O, Baldetorp B, et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat. 2000;1:69-76.
122. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;17:1254-1261. (Pubitemid 41535366)
123. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;30:4772-4778. (Pubitemid 350086480)
124. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;8:1284-1291.
125. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;21:1571-1581. (Pubitemid 44680908)
126. Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006;3(Pt 2):1049s-1055s.
127. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;30:7512-7517. (Pubitemid 46291814)
128. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;5:818-826.
129. Colomer R, Beltran M, Dorcas J, et al. It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol. 2005;16:3868-3389; author reply 3869-3870.
130. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;15:4614-4618. (Pubitemid 44297812)
131. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;4785:177-182. (Pubitemid 17231334)
132. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;8:1007-1014.
133. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;8:2334-2356. (Pubitemid 32366985)
134. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;4:411-417.
135. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;35:5697-5704.
136. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;12:1927-1934.
137. Press MF, Finn RS, Cameron D, et al. HER-HE2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008;23:7861-7870.
138. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;16:1659-1672. (Pubitemid 41464705)
139. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess. 2009;suppl. 1:1-6.
140. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;11:783-792. (Pubitemid 32222155)
141. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010;2:293-308.
142. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA J Am Med Assoc. 2006;21:2492-2502. (Pubitemid 43854964)
143. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. The Breast. 2007;2(suppl 1):72-77. (Pubitemid 350028561)
144. Jung SY, Han W, Lee JW, et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009;5:1112-1121.
145. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;2:174-183.
146. Colozza M, Azambuja E, Cardoso F, et al. Proliferative Markers as Prognostic and Predictive Tools in Early Breast Cancer: Where Are We Now? Ann Oncol. 2005;11:1723-1739.
147. Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008;3:207-212. (Pubitemid 351480546)
148. Colozza M, Sidoni A, Piccart-Gebhart M. Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol. 5:414-415.
149. Baak JP, Gudlaugsson E, Skaland I, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat. 2009;2:241-254.
150. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;10:736-750.
151. Aleskandarany MA, Rakha EA, Macmillan RD, et al. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 2010. PMID 20623333.
152. Aleskandarany MA, Green AR, Rakha EA, et al. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer. 2010;7:1761-1769.
153. Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 1999;4:574-579. (Pubitemid 29192965)
154. Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;4:339-349.
155. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.
156. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;14:8418-8423. (Pubitemid 36842560)
157. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;2:263-280.
158. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;15:2568-2581.
159. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;4:R34.
160. Ambrogi F, Biganzoli E, Querzoli P, et al. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clin Cancer Res. 2006;3(Pt 1):781-790. (Pubitemid 43259858)
161. Cuzick J, Dowsett M, Wale C, et al. Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score - Results from TransATAC. Cancer Res. 2009;69 (Suppl. 24):Abstract 74.
162. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res. 2004;18(Pt 1):6143-6151. (Pubitemid 39287520)
163. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;3:767-779. (Pubitemid 40216434)
164. Soria D, Garibaldi JM, Ambrogi F, et al. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med. 2010;3:318-330.
165. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;11:3207-3214. (Pubitemid 46944903)
166. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX. Expert Rev Mol Diagn. 2006;6:803-809. (Pubitemid 44911030)
167. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;3:R25.
168. Kelly CM, Krishnamurthy S, G Bianchini S, et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010;22:5161-5167.
169. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;18:10393-10398. (Pubitemid 37071889)
170. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;3:217-226. (Pubitemid 46143225)
171. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005;10:3738-3743. (Pubitemid 40354681)
172. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47.
173. Ahr A, Holtrich U, Solbach C, et al. Molecular classification of breast cancer patients by gene expression profiling. J Pathol. 2001;3:312-320.
174. Naoi Y, Kishi K, Tanei T, et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat. 2010. PMID 20803240.
175. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;27:2817-2826. (Pubitemid 40051905)
176. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;11:1829-1834.
177. Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008;2:233-240. (Pubitemid 351311356)
178. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;29:7265-7277. (Pubitemid 46202341)
179. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;17:1183-1192. (Pubitemid 44390989)
180. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;25:1999-2009. (Pubitemid 35461656)
181. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13: IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;28:4611-4619. (Pubitemid 46630959)
182. Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;7(Pt 1):2080-2087.
183. Lusa L, McShane LM, Reid JF, et al. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst. 2007;22:1715-1723. (Pubitemid 351767219)
184. Nuyten DS, Chang HY, Brown PO, et al. Reproducibility of molecular portraits in early stage breast cancer. Breast Cancer Res. 2005;7:P4.
185. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med. 2010;11:1697-1701.
186. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008;5:358-369. (Pubitemid 351665467)